Oximezin (Cefotaxime)

Oximezin is a broad‑spectrum cephalosporin that targets Gram‑negative and Gram‑positive bacterial pathogens in several clinical contexts.

• Lower respiratory tract infections: helps eradicate the causative bacteria and improve pulmonary function.
• Urinary tract infections: eliminates the infecting organisms and reduces symptom duration.
• Intra‑abdominal infections: provides coverage against mixed aerobic and anaerobic flora, aiding recovery.
• Skin and soft‑tissue infections: treats susceptible Staphylococcus and Streptococcus species.
• Septicemia and bacteremia: rapidly clears bacteria from the bloodstream, supporting hemodynamic stability.

• Cefotaxime inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, which blocks the cross‑linking of peptidoglycan strands. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death. The drug shows high affinity for a broad range of Gram‑negative and some Gram‑positive organisms.

Adverse reactions to cefotaxime are generally dose‑related and vary with patient factors.

Common Side Effects

• Diarrhea: mild to moderate watery stools.
• Nausea: occasional upset stomach.
• Rash: transient erythematous skin eruptions.
• Injection site pain: discomfort at the infusion site.
• Elevated liver enzymes: transient increase in hepatic transaminases.
• Headache: mild, self‑limiting.

Serious or Rare Side Effects

• Anaphylaxis: acute, potentially life‑threatening hypersensitivity.
• Stevens‑Johnson syndrome: severe mucocutaneous reaction.
• Clostridioides difficile‑associated colitis: severe diarrhea due to bacterial overgrowth.
• Neutropenia: marked reduction in neutrophil count.
• Renal impairment: acute kidney injury, especially with high doses.
• Hepatotoxicity: significant liver enzyme elevation or jaundice.

When using Oximezin, clinicians should assess patient history and monitor relevant clinical parameters.

• Renal function: adjust dose in patients with impaired clearance.
• Hepatic function: monitor liver enzymes during prolonged therapy.
• Allergy history: avoid in patients with known cephalosporin or penicillin hypersensitivity.
• Concomitant nephrotoxic drugs: use caution to reduce risk of kidney injury.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly indicated.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Cefotaxime may interact with several co‑administered medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Aminoglycosides: increased risk of nephrotoxicity when given together.
• Loop diuretics: heightened potential for ototoxicity.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely)

• Probenecid: reduces renal excretion of cefotaxime, increasing serum levels.
• Oral contraceptives: possible reduction in contraceptive efficacy.
• Antacids containing magnesium or aluminum: may impair absorption if given concurrently.